{"title":"Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment","authors":"Gaurisha alias Resha Ramnath Naik, , , Rachana S P, , , Sandesh Ramchandra Jadhav, , , Rahul Pokale, , , Paniz Hedayat, , , Deepanjan Datta, , , Bhupendra Prajapati, , , Srinivas Mutalik, , and , Namdev Dhas*, ","doi":"10.1021/acsptsci.5c00007","DOIUrl":null,"url":null,"abstract":"<p >Glioblastoma multiforme (GBM) is the most aggressive and prevailing form of primary brain tumor, illustrated by its rapid growth and invasive nature. GBM continues to be highly incurable despite advancements in treatment due to its complex tumor microenvironment (TME) and the unique characteristics of tumor-associated macrophages (TAMs). This review explores the function of macrophages within the TME of GBM, specifically emphasizing the impact of colony-stimulating Factor-1 (CSF-1) and its receptor CSF1R in macrophage biology. The progression, survival, and differentiation of TAMs, which often rely on immunosuppressive properties that contribute to tumor growth and treatment resistance, are facilitated by elevated CSF-1 levels in GBM. The inhibition of CSF1R presents a promising therapeutic strategy, as it selectively targets tumor-promoting macrophages while sparing antitumor macrophages. Preclinical evidence demonstrates improved survival outcomes through CSF1R inhibition in mouse models, highlighting its potential for clinical application. Ongoing clinical trials further investigate this approach, aiming to enhance treatment efficacy for patients with GBM. This review concludes by emphasizing the significance of repolarizing macrophages as a novel therapeutic opportunity in GBM management, alongside emerging trends and future research directions that could lead to breakthroughs in treatment strategies.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 10","pages":"3391–3410"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acsptsci.5c00007","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Glioblastoma multiforme (GBM) is the most aggressive and prevailing form of primary brain tumor, illustrated by its rapid growth and invasive nature. GBM continues to be highly incurable despite advancements in treatment due to its complex tumor microenvironment (TME) and the unique characteristics of tumor-associated macrophages (TAMs). This review explores the function of macrophages within the TME of GBM, specifically emphasizing the impact of colony-stimulating Factor-1 (CSF-1) and its receptor CSF1R in macrophage biology. The progression, survival, and differentiation of TAMs, which often rely on immunosuppressive properties that contribute to tumor growth and treatment resistance, are facilitated by elevated CSF-1 levels in GBM. The inhibition of CSF1R presents a promising therapeutic strategy, as it selectively targets tumor-promoting macrophages while sparing antitumor macrophages. Preclinical evidence demonstrates improved survival outcomes through CSF1R inhibition in mouse models, highlighting its potential for clinical application. Ongoing clinical trials further investigate this approach, aiming to enhance treatment efficacy for patients with GBM. This review concludes by emphasizing the significance of repolarizing macrophages as a novel therapeutic opportunity in GBM management, alongside emerging trends and future research directions that could lead to breakthroughs in treatment strategies.
期刊介绍:
ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered.
ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.
Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.